Reliance Securities has come out with its research report on Claris Lifesciences. “With USFDA resolution, Propofol launch settlement and strong pipeline of injectables, expect better times for the company led by the increasing profitability in operations”, says the report.
| Subscribe To Our Free Newsletter |
